Share Prices & Company Research

Market News

02 Dec 2021 | 07:26

GSK says its Covid-19 treatment works on Omicron

(Sharecast News) - GlaxoSmithKline said its treatment for Covid-19 was effective in treating all tested variants of the virus including key mutations of the Omicron strain. The FTSE 100 drugs company said it had tested Sotrovimab on specific individual mutations found in Omicron and that the treatment had shown activity against all variants of concern defined by the World Health Organization.

GSK said it was working with Vir Technology, its partner on Sotrovimab, to confirm effectiveness against all Omicron mutations. An update is expected by the end of 2021.

Hal Barron, GSK's chief scientific officer, said: "Since the beginning of the pandemic, we have been working with Vir to combine our scientific expertise and technologies to deliver an enduring treatment option for patients with Covid-19. Though early, these pre-clinical data support our long-held view on the potential for Sotrovimab to maintain its activity as the virus continues to mutate."

Sotrovimab has been found to cut the risk of hospitalisation or death by 79% in adults with mild-to-moderate Covid-19. GSK has sold the treatment to the US, the EU and other markets.

The Omicron variant appears to be more transmissible than earlier versions of Covid-19 and may be more resistant to vaccines. The appearance of the strain has affected financial markets and the UK has ordered people to wear masks on public transport and in shops.
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 17th May 2022
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.